Details of the Drug

General Information of Drug (ID: DMZA5PQ)

Drug Name
Glipizide
Synonyms
Aldiab; Digrin; Dipazide; Glibenese; Glibetin; Glican; Glide; Glidiab; Glidiazinamide; Glipid; Glipizida; Glipizidum; Glucolip; Glucotrol; Glucozide; Glupitel; Glupizide; Glyde; Glydiazinamide; Glypidizine; Melizide; Metaglip; Mindiab; Minidab; Minidiab; Minodiab; Napizide; Ozidia; Semiglynase; Sucrazide; Alphapharm Brand of Glipizide; Glibenese Brand of Glipizide; Glipizide Kenfarma Brand; Glucotrol XL; Kenfarma Brand of Glipizide; Lacer Brand of Glipizide; Lilly Brand of Glipizide; CP 28720; K 4024; K4024; PfizerBrand 1 of Glipizide; Pfizer Brand 2 of Glipizide; TK 1320; CP 28,720; CP-28720; G-117; Glipizida [INN-Spanish]; Glipizide Extended-Release Tablets; Glipizidum [INN-Latin]; Gluco-Rite; Glucotrol (TN); K-4024; KS-1068; Samarium(III) ionophore I; Glipizide (USP/INN); Glipizide [USAN:BAN:INN]; Glucotrol XL, Glucotrol, Glipizide; N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide; N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide; N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea; 1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea; 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [1], [2]
Therapeutic Class
Hypoglycemic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 445.5
Topological Polar Surface Area (xlogp) 1.9
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 100% [4]
Clearance
The total body clearance of drug is 3 L/h [5]
Elimination
4.5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 5 hours [6]
Metabolism
The drug is metabolized via the hepatic [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.9619 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.02% [6]
Vd
The volume of distribution (Vd) of drug is 10 L [9]
Chemical Identifiers
Formula
C21H27N5O4S
IUPAC Name
N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide
Canonical SMILES
CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
InChI
InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)
InChIKey
ZJJXGWJIGJFDTL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3478
ChEBI ID
CHEBI:5384
CAS Number
29094-61-9
DrugBank ID
DB01067
TTD ID
D0Z4SB
VARIDT ID
DR00329
INTEDE ID
DR0778
ACDINA ID
D00303

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Inward rectifier potassium channel Kir1.2 (KCNJ10) TTG140O KCJ10_HUMAN Blocker [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Bile salt export pump (ABCB11) DTJ0EW4 ABCBB_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [13]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [14]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Glipizide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Glipizide due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [59]
Tromethamine DMOBLGK Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Glipizide caused by Tromethamine mediated altered urine pH. Acidosis [5C73] [60]
Arn-509 DMT81LZ Moderate Increased metabolism of Glipizide caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [61]
Oxymetholone DMFXUT8 Moderate Increased risk of hypoglycemia by the combination of Glipizide and Oxymetholone. Aplastic anaemia [3A70] [62]
Clarithromycin DM4M1SG Moderate Increased plasma concentration of Glipizide and Clarithromycin due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [63]
Alpelisib DMEXMYK Moderate Increased metabolism of Glipizide caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [64]
Fluoxymesterone DMUHCF1 Moderate Increased risk of hypoglycemia by the combination of Glipizide and Fluoxymesterone. Breast cancer [2C60-2C6Y] [62]
Fenofibric acid DMGO2MC Moderate Increased risk of hypoglycemia by the combination of Glipizide and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [62]
Ardeparin DMYRX8B Moderate Increased risk of hypoglycemia by the combination of Glipizide and Ardeparin. Coronary thrombosis [BA43] [62]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Glipizide caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [65]
MK-8228 DMOB58Q Moderate Increased metabolism of Glipizide caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [66]
Sertraline DM0FB1J Moderate Increased risk of hypoglycemia by the combination of Glipizide and Sertraline. Depression [6A70-6A7Z] [62]
Vilazodone DM4LECQ Moderate Increased risk of hypoglycemia by the combination of Glipizide and Vilazodone. Depression [6A70-6A7Z] [62]
Vortioxetine DM6F1PU Moderate Increased risk of hypoglycemia by the combination of Glipizide and Vortioxetine. Depression [6A70-6A7Z] [62]
Isocarboxazid DMAF1NB Moderate Increased risk of hypoglycemia by the combination of Glipizide and Isocarboxazid. Depression [6A70-6A7Z] [62]
Escitalopram DMFK9HG Moderate Increased risk of hypoglycemia by the combination of Glipizide and Escitalopram. Depression [6A70-6A7Z] [62]
SODIUM CITRATE DMHPD2Y Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Glipizide caused by SODIUM CITRATE mediated altered urine pH. Discovery agent [N.A.] [60]
Miconazole DMPMYE8 Major Decreased metabolism of Glipizide caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [62]
Sunitinib DMCBJSR Moderate Increased risk of hypoglycemia by the combination of Glipizide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [62]
Sulfinpyrazone DMEV954 Moderate Decreased renal excretion of Glipizide caused by Sulfinpyrazone. Gout [FA25] [61]
Rifapentine DMCHV4I Moderate Increased metabolism of Glipizide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [67]
Etravirine DMGV8QU Moderate Decreased metabolism of Glipizide caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [68]
Gemfibrozil DMD8Q3J Moderate Increased risk of hypoglycemia by the combination of Glipizide and Gemfibrozil. Hyper-lipoproteinaemia [5C80] [62]
Captopril DM458UM Moderate Increased risk of hypoglycemia by the combination of Glipizide and Captopril. Hypertension [BA00-BA04] [62]
Sodium acetate anhydrous DMH21E0 Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Glipizide caused by Sodium acetate anhydrous mediated altered urine pH. Hypo-osmolality/hyponatraemia [5C72] [60]
PF-06463922 DMKM7EW Moderate Increased metabolism of Glipizide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [69]
Hydroxychloroquine DMSIVND Moderate Increased risk of hypoglycemia by the combination of Glipizide and Hydroxychloroquine. Malaria [1F40-1F45] [62]
Sulphadoxine DMZI2UF Moderate Increased risk of hypoglycemia by the combination of Glipizide and Sulphadoxine. Malaria [1F40-1F45] [62]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Glipizide caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [69]
Mecasermin DM1O3BY Moderate Increased risk of hypoglycemia by the combination of Glipizide and Mecasermin. Multiple structural anomalies syndrome [LD2F] [62]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Glipizide caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [70]
Safinamide DM0YWJC Moderate Increased risk of hypoglycemia by the combination of Glipizide and Safinamide. Parkinsonism [8A00] [62]
Rasagiline DM3WKQ4 Moderate Increased risk of hypoglycemia by the combination of Glipizide and Rasagiline. Parkinsonism [8A00] [62]
Choline salicylate DM8P137 Moderate Increased risk of hypoglycemia by the combination of Glipizide and Choline salicylate. Postoperative inflammation [1A00-CA43] [62]
Enzalutamide DMGL19D Moderate Increased metabolism of Glipizide caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [71]
Salsalate DM13P4C Moderate Increased risk of hypoglycemia by the combination of Glipizide and Salsalate. Rheumatoid arthritis [FA20] [62]
Leflunomide DMR8ONJ Moderate Decreased metabolism of Glipizide caused by Leflunomide mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [72]
Ifosfamide DMCT3I8 Moderate Increased risk of hypoglycemia by the combination of Glipizide and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [62]
Methyltestosterone DMWLFGO Moderate Increased risk of hypoglycemia by the combination of Glipizide and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [62]
Pramlintide DM0EZ9Q Moderate Increased risk of hypoglycemia by the combination of Glipizide and Pramlintide. Type-1/2 diabete [5A10-5A11] [62]
Olsalazine DMZW9HA Moderate Increased risk of hypoglycemia by the combination of Glipizide and Olsalazine. Ulcerative colitis [DD71] [62]
⏷ Show the Full List of 41 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Butylated hydroxytoluene E00336 31404 Antioxidant
FD&C blue no. 2 E00446 2723854 Colorant
Glyceryl monostearate E00310 24699 Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Sodium stearyl fumarate E00545 23665634 lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Acetyltributyl citrate E00127 6505 Plasticizing agent
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 28 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Glipizide 2.5 mg tablet 2.5 mg 24 HR Extended Release Oral Tablet Oral
Glipizide 5 mg tablet 5 mg 24 HR Extended Release Oral Tablet Oral
Glipizide 10 mg tablet 10 mg 24 HR Extended Release Oral Tablet Oral
Glipizide 10 mg tablet 10 mg Oral Tablet Oral
Glipizide 5 mg tablet 5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6821).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074223.
3 BDDCS applied to over 900 drugs
4 Melander A, Wahlin-Boll E: Clinical pharmacology of glipizide. Am J Med. 1983 Nov 30;75(5B):41-5.
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Glipizide 5 mg Tablets - Summary of Product Characteristics (SmPC) - European Medicines Agency
10 Triggering and amplification of insulin secretion by dimethyl alpha-ketoglutarate, a membrane permeable alpha-ketoglutarate analogue. Eur J Pharmacol. 2009 Apr 1;607(1-3):41-6.
11 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
12 Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Pharmacoeconomics. 2004;22(6):389-411.
13 Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005 Jan;77(1):1-16.
14 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
15 Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999 Feb;9(1):71-80.
16 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
25 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
26 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
27 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
28 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
29 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
30 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
31 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
32 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
33 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
34 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
35 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
36 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
37 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
38 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
39 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
40 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
41 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
42 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
43 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
44 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
45 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
46 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
47 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
48 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
49 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
50 Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther. 2005 Aug;314(2):876-82.
51 Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol. 2002 Jul 1;64(1):151-8.
52 Effect of the chlorpropamide and fructose-1,6-bisphosphate of soluble TNF receptor II levels. Pharmacol Res. 2004 May;49(5):449-53.
53 Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther. 2006 Jan;316(1):182-8.
54 Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem. 2003 May 1;11(9):2099-113.
55 Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe hemorrhagic shock. Shock. 1996 Jun;5(6):391-4.
56 Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol. 2007 Jun 1;73(11):1842-51.
57 Coupling between proximal tubular transport processes. Studies with ouabain, SITS and HCO3-free solutions. Pflugers Arch. 1977 Apr 25;368(3):245-52.
58 Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98.
59 Kivisto KT, Neuvonen PJ "Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide." Eur J Clin Pharmacol 42 (1992): 675-80. [PMID: 1623912]
60 Kivisto KT, Neuvonen PJ "Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide." Eur J Clin Pharmacol 40 (1991): 383-6. [PMID: 1646724]
61 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
62 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
63 Bussing R, Gende A "Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction." Diabetes Care 25 (2002): 1659-61. [PMID: 12196446]
64 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
65 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
66 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
67 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
68 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
69 Cerner Multum, Inc. "Australian Product Information.".
70 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
71 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
72 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.